Information Provided By:
Fly News Breaks for January 15, 2020
Jan 15, 2020 | 07:37 EDT
Cowen analyst Joshua Jennings thinks the pullback in Boston Scientific shares in response to Q4 sales results and its second quarterly miss this year, is an overdone. He believes investors should have confidence in the outlook for 2020 and beyond, especially given its lineup of new product launches. Jennings said he would use the weakness as a buying opportunity and he reiterated his Outperform rating and $52 price target on Boston Scientific shares.
News For BSX From the Last 2 Days
There are no results for your query BSX